Osteopetrosis and related disorders

Osteopetrosis and related disorders (Orphanet code 2781) comprise a group of rare hereditary skeletal diseases characterized by increased bone density due to defective osteoclast-mediated bone resorption. The term osteopetrosis, also known as marble bone disease or Albers-Schönberg disease, reflects the abnormally dense, "stone-like" quality of affected bones. Despite appearing denser on imaging, the bone is structurally abnormal and often more brittle, leading to an increased risk of fractures. The condition primarily affects the skeletal system but has significant secondary effects on the hematopoietic system, nervous system, and immune system. As abnormally dense bone encroaches on the marrow cavity, patients may develop bone marrow failure (pancytopenia), leading to anemia, recurrent infections, and bleeding tendencies. Cranial nerve compression — particularly of the optic and facial nerves — can cause blindness, deafness, and facial palsy. Hepatosplenomegaly may occur due to extramedullary hematopoiesis as the body compensates for reduced marrow space. Several clinical forms are recognized. The autosomal recessive (infantile or malignant) form is the most severe, typically presenting in infancy with failure to thrive, macrocephaly, bone marrow failure, and cranial nerve deficits; without treatment, it is often fatal in early childhood. The autosomal dominant (adult) form, classically known as Albers-Schönberg disease (type II), is milder and may present in late childhood or adulthood with fractures, osteomyelitis (particularly of the jaw), and mild anemia. Intermediate autosomal recessive forms also exist. Causative genes include TCIRG1, CLCN7, OSTM1, SNX10, TNFSF11 (RANKL), TNFRSF11A (RANK), and others involved in osteoclast differentiation or function. The treatment landscape varies by disease severity. For severe infantile osteopetrosis, hematopoietic stem cell transplantation (HSCT) remains the only curative option and is most effective when performed early in life, particularly for forms caused by osteoclast-intrinsic defects (e.g., TCIRG1 mutations). Supportive care includes management of fractures, treatment of infections, calcium and vitamin D monitoring, transfusion support, and surgical decompression of compressed cranial nerves. Interferon gamma-1b has been used in some cases to improve immune function and reduce bone density. Gene therapy approaches are under investigation for certain genetic subtypes. For milder adult forms, management is primarily symptomatic, focusing on fracture prevention, orthopedic care, and surveillance for complications such as osteomyelitis.

Common questions about Osteopetrosis and related disorders